Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Tazemetostat Tazverik 200mg Chemotherapy Enzyme Inhibitor EZH2 Yes 2020 In Use
BA Belzutifan Welireg 40mg Chemotherapy Miscellaneous Agent HIF-2 alpha Yes 2021 In Use
J1932 Lanreotide (Cipla) Lanreotide Acetate 1mg Hormonal Therapy Somatostatin Analog No 2021 Sep 27, 2022 In Use
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sep 27, 2021 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
C9078 Trilaciclib Cosela 1mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDX 4/6 No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan 26, 2022 In Use
NA Tepotinib Hydrochloride Tepmetko 225mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2021 In Use
C9087 Cyclophosphamide (Auromedics) Cyclophosphamide 10mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Jan 26, 2022 Mar 25, 2022 No Longer Used
C9083 Amivantamab-vmjw Rybrevant 10mg Immunotherapy Monoclonal Antibody EGFR,MET No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
Q5112 Trastuzumab-dttb Ontruzant 10mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 1, 2019 In Use
J9273 Tisotumab vedodin-tftv Tivdak 1mg Immunotherapy Drug Antibody Conjugate Tissue factor No 2021 Mar 25, 2022 In Use
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
C9080 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
C9084 Loncastuximab tesirine Zylonta 0.1mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Sep 27, 2021 Mar 25, 2022 In Use
C9082 Dostarlimab-gxly Jemperli 100mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
J1448 Trilaciclib Cosela 1mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 No 2021 Sep 27, 2021 In Use
C9076 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
J9247 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Sep 27, 2021 Mar 26, 2025 No Longer Used
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
J9272 Dostarlimab-gxly Jemperli 10mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Jan 26, 2022 In Use
Q2055 Idecabtagene vicleucel Abecma 460 million Immunotherapy CAR-T BCMA No 2021 Jan 26, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.